News for LifeStance Health Group, Inc. (LFST)

LifeStance Health Group, Inc. (NASDAQ:LFST) is one of the 13 Stocks Under $5 With High Upside Potential.

LifeStance Health Group, Inc. (NASDAQ:LFST) is one of the 13 Stocks Under $5 With High Upside Potential. On May 27, Morgan Stanley analyst Craig Hettenbach maintained a Buy rating on LifeStance Health Group, Inc. (NASDAQ:LFST), keeping the associated price target the same at $10. The analyst based the rating on the company’s growth potential and strategic […]

LifeStance Health is showing a real turnaround, posting its first-ever net profit and rapidly expanding margins. Learn more about LFST stock now.

On June 6, 2025, TPG GP A, LLC (Trades, Portfolio) executed a significant transaction involving Life Time Group Holdings Inc (LTH). The firm reduced its holding

The heavy selling pressure might have exhausted for LifeStance Health (LFST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

The consensus price target hints at a 45% upside potential for LifeStance Health (LFST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

**media[639749]**

UBS analyst Kevin Caliendo raised the rating of LifeStance Health Group, Inc. (NASDAQ:LFST) from Neutral to Buy on May 27, with an unchanged price target of $8.50. Caliendo ascribes the boost to investor de-risking and possible misunderstandings of recent corporate developments, which followed a period of downturn for the LFST stock. Despite a cautious forecast […]

UBS analyst Kevin Caliendo raised the rating of LifeStance Health Group, Inc. (NASDAQ:LFST) from Neutral to Buy on May 27, with an unchanged price target of $8.50.

LifeStance Health (LFST) receives an upgrade from UBS, now rated as a Buy with a price target suggesting potential growth. Analysts predict significant

On May 27, 2025, LifeStance Health Group (LFST) received an upgrade from UBS, with analyst Kevin Caliendo shifting the stock rating from "Neutral" to "Buy." Thi

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

UBS analyst Kevin Caliendo has elevated LifeStance (LFST) to a Buy rating from Neutral, maintaining the target price at $8.50. This upgrade stems from the belie

PR NewswireSCOTTSDALE, Ariz., May 14, 2025 SCOTTSDALE, Ariz., May 14, 2025 /PRNewswire/ -- LifeStance Health, one of the nation's largest providers of virt

LifeStance Health (LFST) has announced the appointment of Vaughn Paunovich as its new Chief Technology Officer, effective June 9. Paunovich will spearhead the c

LifeStance Health Group, Inc. (NASDAQ:LFST) Q1 2025 Results Conference Call May 7, 2025 8:30 AM ETCompany ParticipantsMonica Prokocki - VP, IRRyan McGroarty...

LifeStance Health (LFST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

LifeStance Health (LFST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Revenue: Achieved $333.0 million, surpassing the estimated $332.90 million and marking an 11% increase year-over-year.Earnings Per Share (EPS): Reported at $0.